Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21025)Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / Melanoma Manag 2019 May;6(2):MMT20STAT3 Contributes To Oncolytic Newcastle Disease Virus-Induced Immunogenic Cell Death in Melanoma Cells
/in Immunogenic Cell Death, International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2019-05-29 / Front Oncol 2019;9:436Melanoma vaccines: clinical status and immune endpoints
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-04-01 / Melanoma Res. 2019 04;29(2):109-118Health-related quality of life analysis in stage III melanoma patients treated with adjuvant dendritic cell therapy
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-11-21 / Clin Transl Oncol 2019 Jun;21(6):774-780Combining Tumor Vaccination and Oncolytic Viral Approaches with Checkpoint Inhibitors: Rationale, Pre-Clinical Experience, and Current Clinical Trials in Malignant Melanoma
/in Checkpoint-Inhibitors, Dendritic Cells, International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2018-10-01 / Am J Clin Dermatol 2018 Oct;19(5):657-670The Current Status and Future Prospects of Oncolytic Viruses in Clinical Trials against Melanoma, Glioma, Pancreatic, and Breast Cancers
/in Breast Cancer, Glioblastoma, International Publications, Malignant Melanoma, Newcastle Disease Virus, Pancreatic Cancer /von 2018-09-26 / Cancers (Basel) 2018 Sep;10(10)The Role of Oncolytic Viruses in the Treatment of Melanoma
/in International Publications, Malignant Melanoma, Newcastle Disease Virus /von 2018-08-25 / Curr Oncol Rep 2018 08;20(10):80Complementary vaccination protocol with dendritic cells pulsed with autologous tumour lysate in patients with resected stage III or IV melanoma: protocol for a phase II randomised trial (ACDC Adjuvant Trial)
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2018-08-05 / BMJ Open 2018 08;8(8):e021701
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Das IOZK
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- From Localized Mild Hyperthermia to Improved Tumor Oxygenation: Physiological Mechanisms Critically Involved in Oncologic Thermo-Radio-Immunotherapy
- Individualized Multimodal Immunotherapy for Adults with IDH1 Wild-Type GBM: A Single Institute Experience
- Immunotherapy in breast cancer: an overview of current strategies and perspectives